Glyco-variants of Recombinant Proteins
Glycosylation of proteins can have significant effect on activity, immunogenicity, stability and more, and is one of the critical attributes to monitor when producing biologics. Controlling glycosylation can result in more potent drugs, easier process development and manufacturing, and serve as a research tool to understand the effects of glycosylation on proteins.
Through our partner at the National Biologics Facility (NBF) under the Technical University of Denmark, we can offer the production of glycoproteins with bespoke glycosylation. By targeted, precision genome engineering over more than a decade, the NBF has generated a panel of GMP-ready CHO cell lines for the production of proteins with defined glycosylation. Using the panel, we produce variants of glycoproteins, each with a defined and specific glycosylation profile, enabling screening for the optimal glycosylation of therapeutic recombinant proteins. The cell line(s) producing the optimal glycovariant, can be moved forward into classical cell line development, upscaling and manufacturing.
For further information
please contact:
